logo
Plus   Neg
Share
Email

Novartis: CHMP Adopts Positive Opinion On Approval Of Lucentis - Quick Facts

Novartis (NVS) said the Committee of the European Medicines Agency has recommended approval of Lucentis for the treatment of preterm infants with retinopathy of prematurity. If approved, Lucentis (ranibizumab) will be the first and only pharmacological therapy for this patient population.

The CHMP adopted the positive opinion based on the landmark Phase III RAINBOW trial, which showed that Lucentis (ranibizumab) is an efficacious and safe treatment for infants with retinopathy of prematurity. The European Commission is expected to deliver its final decision within three months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken. The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement.
Follow RTT
>